Adage Capital Management, L.P. filed an amended Schedule 13G with the SEC on November 12, 2026, disclosing a beneficial ownership position in Opus Genetics, Inc. common stock as of September 30, 2026.

Key Highlights

  • Reporting persons: Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross are the three reporting persons named in the filing.
  • Shares beneficially owned: Each reporting person lists 2,254,996 shares of Opus Genetics common stock (par value $0.0001 per share) as beneficially owned.
  • Percent of class: The 2,254,996 shares represent 2.71% of the outstanding common stock, according to the filing.
  • Voting and dispositive power: All 2,254,996 shares are held with shared voting and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Share count basis: The percentage is calculated using 83,195,823 shares outstanding as of August 3, 2026, as reported in the company's quarterly report for the period ended June 30, 2026.
  • Event date: The date of the event requiring this filing is stated as September 30, 2026.

Adage Capital's Amended Ownership Position in Opus Genetics

According to the filing, Adage Capital Management, L.P. ("ACM"), a Delaware limited partnership, serves as the investment manager of Adage Capital Partners, L.P. ("ACP"), which directly holds the 2,254,996 shares of Opus Genetics, Inc. common stock reported here. Opus Genetics is a Delaware corporation with principal executive offices located at 8 Davis Drive, Durham, North Carolina 27713. The shares carry a par value of $0.0001 per share and are identified by CUSIP number 67577R102.

Robert Atchinson and Phillip Gross are each identified as reporting persons in their capacity as managing members of several affiliated entities within the Adage Capital structure, including Adage Capital Advisors, L.L.C. and Adage Capital Partners GP, L.L.C. The filing states that the business address for all reporting persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. The filing notes that it is Amendment No. 1 to a prior Schedule 13G, and the certification language states the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Under Item 5, the filing designates the position as ownership of 5 percent or less of the class. No sole voting or dispositive power is reported for any of the three reporting persons; all voting and dispositive authority over the 2,254,996 shares is listed as shared among the reporting persons in connection with ACP's direct holdings.

What Was Disclosed

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, disclosed a combined beneficial ownership of 2,254,996 shares of Opus Genetics, Inc. common stock, equal to 2.71% of the class, as of September 30, 2026, in this amended Schedule 13G filing.